QIAGEN delivers Sample to Insights solutions that enable customers to unlock insights from the building blocks of life - DNA, RNA and proteins. Thierry Bernard is the company's Chief Executive Officer. In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's diagnostic instruments. QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The main operative headquarters are located in Hilden, QIAGEN is a worldwide provider of molecular sample and assay technologies. Sample technologies are used to collect samples of tissue, fluids, etc. and stabilize, extract and purify various molecules of interest such as DNA, RNA or proteins from other cellular components. Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales reached US$649.8 million and the number of employees surpassed 2,600. Qiagen acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention. QIAGEN has a holding structure. The holding (QIAGEN N.V.) is located in Venlo, The Netherlands. The operative and European headquarters are located in Hilden, Germany. Further regional headquarters are located in Maryland for North America and Shanghai for Asia. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries. QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA).
Anna-maria Ferchichi özil Geld, Immobilien Neumarkt An Der Raab, Superintendentin Kreuzworträtsel, Alice Weidel Freundin Sarah Bossard, Eheim Netzteil Für Power Led 40 Watt,
Commentaires récents